NASDAQ · BDX
Healthcare · Medical - Instruments & Supplies
$183.75
Up+$1.00 (+0.55%)
Updated Oct 12, 2026, 9:02 AM
SID Score
5.5/10
Composite research score
Smart Money
47/100
Neutral
Price performance · BDX
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
BDX closed at $183.75 after 20 trading sessions, up 0.46% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $181.89 | $183.85 | $181.51 | $183.75 | 1.62M |
| Oct 8, 2026 | $179.76 | $182.76 | $178.90 | $182.75 | 1.52M |
| Oct 7, 2026 | $180.34 | $182.38 | $177.915 | $180.16 | 1.92M |
| Oct 6, 2026 | $183.35 | $187.45 | $180.1219 | $180.30 | 2.05M |
| Oct 5, 2026 | $176.58 | $180.90 | $176.04 | $180.67 | 1.64M |
| Oct 2, 2026 | $177.46 | $178.13 | $175.71 | $176.80 | 1.87M |
| Oct 1, 2026 | $179.11 | $179.665 | $177.02 | $178.07 | 1.29M |
| Sep 30, 2026 | $181.19 | $182.34 | $178.91 | $179.00 | 1.8M |
| Sep 29, 2026 | $182.51 | $182.95 | $180.09 | $181.97 | 1.53M |
| Sep 28, 2026 | $183.07 | $184.34 | $181.95 | $183.83 | 1.89M |
| Sep 25, 2026 | $179.22 | $183.92 | $177.87 | $183.82 | 1.47M |
| Sep 24, 2026 | $182.73 | $183.72 | $178.98 | $179.23 | 1.4M |
| Sep 23, 2026 | $182.10 | $184.37 | $181.31 | $182.52 | 1.02M |
| Sep 22, 2026 | $182.40 | $183.8301 | $180.75 | $183.00 | 1.46M |
| Sep 21, 2026 | $181.25 | $181.53 | $179.98 | $180.70 | 1.46M |
| Sep 18, 2026 | $179.76 | $182.615 | $179.42 | $180.94 | 6.42M |
| Sep 17, 2026 | $182.71 | $184.34 | $181.27 | $181.38 | 1.84M |
| Sep 16, 2026 | $185.18 | $186.27 | $181.29 | $181.85 | 1.73M |
| Sep 15, 2026 | $182.39 | $186.63 | $181.28 | $185.92 | 2.09M |
| Sep 14, 2026 | $180.05 | $183.53 | $179.60 | $182.91 | 1.63M |
The latest Smart Investors Daily articles mentioning BDX.
Company
Market Activity
Research & News
BDX research
Company profile and research snapshot.
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. BD Medical is nearly half of the total business, while BD Life Sciences (26% of 2024 revenue) and BD Interventional (25%) account for the remainder. International revenue accounts for 43% of the company's business.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 7, 2026 | Barclays | Underweight | — |
| Aug 31, 2026 | B of A Securities | Neutral | — |
| Aug 13, 2026 | RBC Capital | Sector Perform | — |
| Aug 7, 2026 | Piper Sandler | Neutral | — |
| Aug 7, 2026 | RBC Capital | Sector Perform | — |
Generated Oct 11, 2026, 9:09 PM
Becton Dickinson gained 0.55% today as investors digest positive clinical trial results and anticipation builds ahead of the company's next earnings report. The modest rally reflects cautious optimism about BDX's operational performance and pipeline strength, though broader sentiment remains measured.
Bottom line: BDX's modest gains reflect genuine progress on the clinical front with AGILITY trial success, but investor sentiment remains cautiously optimistic rather than enthusiastic. The key inflection point will be the next earnings report, where management must convincingly bridge the gap between positive trial data and accelerating financial performance—watch for guidance revisions and commentary on commercial execution to determine if the stock can re-rate higher.
Yahoo · Oct 9, 2026
Becton Dickinson (BDX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Yahoo · Oct 9, 2026
Becton Dickinson (BDX) just put fresh clinical data in front of investors. Nine-month results from the AGILITY trial for its Revello Vascular Covered Stent showed the study hit its primary endpoint in iliac artery disease. Recent clinical progress comes on top of a busy October for Becton Dickinson, including a new U.S. government manufacturing partnership and a leadership change in its Surgery unit, while a separate product recall underscored ongoing execution risk across the...
Yahoo · Oct 8, 2026
BD (Becton, Dickinson and Company) recently announced a landmark partnership with the U.S. government to expand domestic manufacturing of essential medical consumables, including a planned US$19.00 billion multi-year investment and a goal to produce all U.S. needles domestically using American-made steel while receiving relief from certain future Section 232 tariffs. This move materially deepens BD’s role in U.S. healthcare infrastructure by tying long-term capital deployment directly to...
Yahoo · Oct 8, 2026
BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, the Global Surgery Foundation (GSF) and the Business Council for International Understanding (BCIU) brought together healthcare, government, academia, and industry leaders to advance solutions aimed at reducing maternal mortality worldwide. On the sidelines of the 81st United Nations General Assembly (UNGA), participants explored how continuous noninvasive blood pressure monitoring and advanced hemodynam
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning BDX.
